StockData
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

NOVAVAX INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.82−0.44 (-3.91%)

Close on Oct 19, 2026

Market cap
$1.78B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026Before market open$57.00M$-0.32–
Q1 FY2026
Ended Mar 31, 2026
May 6, 2026Before market open$140.00M$-0.06–
Q4 FY2025
Ended Dec 31, 2025
Feb 26, 2026Before market open$147.00M$0.11–
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025Before market open$70.00M$-1.25–
Q2 FY2025
Ended Jun 30, 2025
Aug 6, 2025Before market open$239.00M$0.62–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open$667.00M$2.93–
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025Before market open$88.00M$-0.51–
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open$85.00M$-0.76–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 10, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 28, 2024Before market open–––

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Combined R&D and SG&A ExpensesGAAPFull Year 2026$370.00M to $410.00MNew
Non-GAAP Combined R&D and SG&A Expensesnon-GAAPFull Year 2026$310.00M to $340.00MMaintained
Adjusted Licensing, Royalties and Other Revenuenon-GAAPFull Year 2026$155.00M to $175.00MRaised
Adjusted Supply Salesnon-GAAPFull Year 2026$45.00M to $55.00MLowered
Adjusted Total Revenuenon-GAAP2026$235.00M to $275.00MRaised
Nuvaxovid Product SalesFull Year 2026$35.00M to $45.00MLowered

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Novavax filed with the SEC